<?xml version='1.0' encoding='utf-8'?>
<document id="29239016"><sentence text="Intestinal and hepatic contributions to the pharmacokinetic interaction between gamithromycin and rifampicin after single-dose and multiple-dose administration in healthy foals."><entity charOffset="80-93" id="DDI-PubMed.29239016.s1.e0" text="gamithromycin" /><entity charOffset="98-108" id="DDI-PubMed.29239016.s1.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.29239016.s1.e0" e2="DDI-PubMed.29239016.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29239016.s1.e0" e2="DDI-PubMed.29239016.s1.e1" /></sentence><sentence text="Standard treatment of foals with severe abscessing lung infection caused by Rhodococcus equi using rifampicin and a macrolide antibiotic can be compromised by extensive inhibition and/or induction of drug metabolising enzymes (e"><entity charOffset="99-109" id="DDI-PubMed.29239016.s2.e0" text="rifampicin" /><entity charOffset="116-125" id="DDI-PubMed.29239016.s2.e1" text="macrolide" /><pair ddi="false" e1="DDI-PubMed.29239016.s2.e0" e2="DDI-PubMed.29239016.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29239016.s2.e0" e2="DDI-PubMed.29239016.s2.e1" /></sentence><sentence text="g" /><sentence text=" CYP3A4) and transport proteins (e" /><sentence text="g" /><sentence text=" P-glycoprotein), as has been shown for rifampicin and clarithromycin"><entity charOffset="40-50" id="DDI-PubMed.29239016.s6.e0" text="rifampicin" /><entity charOffset="55-69" id="DDI-PubMed.29239016.s6.e1" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.29239016.s6.e0" e2="DDI-PubMed.29239016.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29239016.s6.e0" e2="DDI-PubMed.29239016.s6.e1" /></sentence><sentence text=" The combination of rifampicin with the new, poorly metabolised gamithromycin, a long-acting analogue of azithromycin and tulathromycin with lower pharmacokinetic interaction potential, might be a suitable alternative"><entity charOffset="20-30" id="DDI-PubMed.29239016.s7.e0" text="rifampicin" /><entity charOffset="64-77" id="DDI-PubMed.29239016.s7.e1" text="gamithromycin" /><entity charOffset="105-117" id="DDI-PubMed.29239016.s7.e2" text="azithromycin" /><entity charOffset="122-135" id="DDI-PubMed.29239016.s7.e3" text="tulathromycin" /><pair ddi="false" e1="DDI-PubMed.29239016.s7.e0" e2="DDI-PubMed.29239016.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29239016.s7.e0" e2="DDI-PubMed.29239016.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29239016.s7.e0" e2="DDI-PubMed.29239016.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29239016.s7.e0" e2="DDI-PubMed.29239016.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29239016.s7.e1" e2="DDI-PubMed.29239016.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29239016.s7.e1" e2="DDI-PubMed.29239016.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29239016.s7.e1" e2="DDI-PubMed.29239016.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29239016.s7.e2" e2="DDI-PubMed.29239016.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29239016.s7.e2" e2="DDI-PubMed.29239016.s7.e3" /></sentence><sentence text="" /><sentence text="To evaluate the pharmacokinetic interactions and pulmonary distribution of rifampicin and gamithromycin in healthy foals, and to investigate the cellular uptake of gamithromycin in vitro"><entity charOffset="75-85" id="DDI-PubMed.29239016.s9.e0" text="rifampicin" /><entity charOffset="90-103" id="DDI-PubMed.29239016.s9.e1" text="gamithromycin" /><entity charOffset="164-177" id="DDI-PubMed.29239016.s9.e2" text="gamithromycin" /><pair ddi="false" e1="DDI-PubMed.29239016.s9.e0" e2="DDI-PubMed.29239016.s9.e0" /><pair ddi="false" e1="DDI-PubMed.29239016.s9.e0" e2="DDI-PubMed.29239016.s9.e1" /><pair ddi="false" e1="DDI-PubMed.29239016.s9.e0" e2="DDI-PubMed.29239016.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29239016.s9.e1" e2="DDI-PubMed.29239016.s9.e1" /><pair ddi="false" e1="DDI-PubMed.29239016.s9.e1" e2="DDI-PubMed.29239016.s9.e2" /></sentence><sentence text="" /><sentence text="Controlled, four-period, consecutive, single-dose and multiple-dose study" /><sentence text="" /><sentence text="Pharmacokinetics and lung distribution of rifampicin (10 mg/kg) and gamithromycin (6 mg/kg) were measured in nine healthy foals using LC-MS/MS"><entity charOffset="42-52" id="DDI-PubMed.29239016.s13.e0" text="rifampicin" /><entity charOffset="68-81" id="DDI-PubMed.29239016.s13.e1" text="gamithromycin" /><pair ddi="false" e1="DDI-PubMed.29239016.s13.e0" e2="DDI-PubMed.29239016.s13.e0" /><pair ddi="false" e1="DDI-PubMed.29239016.s13.e0" e2="DDI-PubMed.29239016.s13.e1" /></sentence><sentence text=" Enzyme induction was confirmed using the 4β-OH-cholesterol/cholesterol ratio"><entity charOffset="42-59" id="DDI-PubMed.29239016.s14.e0" text="4β-OH-cholesterol" /><entity charOffset="60-71" id="DDI-PubMed.29239016.s14.e1" text="cholesterol" /><pair ddi="false" e1="DDI-PubMed.29239016.s14.e0" e2="DDI-PubMed.29239016.s14.e0" /><pair ddi="false" e1="DDI-PubMed.29239016.s14.e0" e2="DDI-PubMed.29239016.s14.e1" /></sentence><sentence text=" Affinity of gamithromycin to drug transport proteins was evaluated in vitro using equine hepatocytes and MDCKII-cells stably transfected with human OATP1B1, OATP1B3 and OATP2B1"><entity charOffset="13-26" id="DDI-PubMed.29239016.s15.e0" text="gamithromycin" /></sentence><sentence text="" /><sentence text="Rifampicin significantly (P&lt;0"><entity charOffset="0-10" id="DDI-PubMed.29239016.s17.e0" text="Rifampicin" /></sentence><sentence text="05) increased the plasma exposure of gamithromycin (16"><entity charOffset="37-50" id="DDI-PubMed.29239016.s18.e0" text="gamithromycin" /></sentence><sentence text="2 ± 4" /><sentence text="77 vs" /><sentence text=" 8" /><sentence text="57 ± 3" /><sentence text="10 μg × h/mL) by decreasing the total body clearance" /><sentence text=" Otherwise, gamithromycin significantly lowered plasma exposure of single- and multiple-dose rifampicin (83"><entity charOffset="12-25" id="DDI-PubMed.29239016.s24.e0" text="gamithromycin" /><entity charOffset="93-103" id="DDI-PubMed.29239016.s24.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.29239016.s24.e0" e2="DDI-PubMed.29239016.s24.e0" /><pair ddi="false" e1="DDI-PubMed.29239016.s24.e0" e2="DDI-PubMed.29239016.s24.e1" /></sentence><sentence text="8 ± 35" /><sentence text="3 and 112 ± 43" /><sentence text="1 vs" /><sentence text=" 164 ± 96" /><sentence text="7 μg × h/mL) without a change in metabolic ratio and half-life" /><sentence text=" Gamithromycin was identified as an inhibitor of human OATP1B1, OATP1B3 and OATP2B1 and as a substrate of OATP2B1"><entity charOffset="1-14" id="DDI-PubMed.29239016.s30.e0" text="Gamithromycin" /></sentence><sentence text=" In addition, it was extracted by equine hepatocytes via a mechanism which could be inhibited by rifampicin"><entity charOffset="97-107" id="DDI-PubMed.29239016.s31.e0" text="rifampicin" /></sentence><sentence text="" /><sentence text="Influence of gamithromycin on pulmonary distribution of rifampicin was not evaluated"><entity charOffset="13-26" id="DDI-PubMed.29239016.s33.e0" text="gamithromycin" /><entity charOffset="56-66" id="DDI-PubMed.29239016.s33.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.29239016.s33.e0" e2="DDI-PubMed.29239016.s33.e0" /><pair ddi="false" e1="DDI-PubMed.29239016.s33.e0" e2="DDI-PubMed.29239016.s33.e1" /></sentence><sentence text="" /><sentence text="The plasma exposure of gamithromycin is significantly increased by co-administration of rifampicin which is most likely caused by inhibition of hepatic elimination"><entity charOffset="23-36" id="DDI-PubMed.29239016.s35.e0" text="gamithromycin" /><entity charOffset="88-98" id="DDI-PubMed.29239016.s35.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.29239016.s35.e0" e2="DDI-PubMed.29239016.s35.e0" /><pair ddi="false" e1="DDI-PubMed.29239016.s35.e0" e2="DDI-PubMed.29239016.s35.e1" /></sentence><sentence text="" /></document>